Investment Thesis — Plexus Corp.
The market is pricing Plexus Corp. as a mature contract manufacturer, ignoring its accelerating exposure to high-margin, mission-critical tech verticals. Investors underestimate the compounding effect of Plexus’s deep integration into clients’ R&D cycles, which insulates revenue and expands pricing power.
Catalysts
- Winning large contracts in medical or aerospace tech
- Demonstrating sustained margin expansion
- Announcing strategic partnerships with major OEMs
Risk Factors
- Customer concentration leading to revenue volatility
- Tech hardware cycle downturn
- Increased competition from global contract manufacturers
Key Debates
Gross Margins Exceed 11% by Q4, Driving P/E Re-rate
Revenue Growth Accelerates Past 15% by H1, Elevating P/S
ROE Rises Above 14% by FY25 as Buybacks Accelerate